{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.2","upperLimit":"36.1","value":"14.5"},{"groupId":"OG001","lowerLimit":"3.0","upperLimit":"16.1","value":"12.7"},{"groupId":"OG002","lowerLimit":"6.8","upperLimit":"22.0","value":"14.7"},{"groupId":"OG003","lowerLimit":"6.4","upperLimit":"15.2","value":"8.1"},{"groupId":"OG004","lowerLimit":"7.7","upperLimit":"16.9","value":"10.7"},{"comment":"Upper limit of 95% CI was not estimable as there were less number of participants with an event.","groupId":"OG005","lowerLimit":"4.7","upperLimit":"NA","value":"10.9"},{"comment":"Upper limit of 95% CI was not estimable as there were less number of participants with an event.","groupId":"OG006","lowerLimit":"0.4","upperLimit":"NA","value":"11.3"},{"groupId":"OG007","lowerLimit":"6.9","upperLimit":"18.9","value":"12.8"},{"comment":"Upper limit of 95% CI was not estimable as there were less number of participants with an event.","groupId":"OG008","lowerLimit":"5.8","upperLimit":"NA","value":"29.3"},{"comment":"Upper limit of 95% CI was not estimable as there were less number of participants with an event.","groupId":"OG009","lowerLimit":"3.4","upperLimit":"NA","value":"22.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"35"},{"groupId":"OG005","value":"21"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"21"},{"groupId":"OG008","value":"11"},{"groupId":"OG009","value":"11"}],"units":"Participants"}],"description":"OS was defined as the time (in months) from the date of first dose of study drug to the date of death due to any cause or data censoring date, whichever occurred first. Participants last known to be alive were censored at the date of last contact. OS was analyzed by Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"During phase 1b participants with Non-Small Cell Lung Cancer (NSCLC) received utomilumab 500 mg intravenously (IV) every 4 weeks (Q4W) with 10 milligrams per kilogram (mg/kg) of avelumab administered IV every 2 weeks (Q2W) for 2 cycles, where each cycle was of 4 weeks.","id":"OG000","title":"Combination A Phase 1b NSCLC: Utomilumab 500 mg + Avelumab"},{"description":"During phase 1b participants with NSCLC received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG001","title":"Combination A Phase 1b NSCLC: Utomilumab 100 mg + Avelumab"},{"description":"During phase 1b participants with NSCLC received utomilumab 20 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG002","title":"Combination A Phase 1b NSCLC: Utomilumab 20 mg + Avelumab"},{"description":"During Phase 2 participants with melanoma received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG003","title":"Combination A Phase 2 Melanoma: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with Squamous Cell Carcinoma of the Head and Neck (SCCHN) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG004","title":"Combination A Phase 2 SCCHN: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with Triple Negative Breast Cancer (TNBC) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG005","title":"Combination A Phase 2 TNBC: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with Squamous cell lung cancer (SCLC) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG006","title":"Combination A Phase 2 SCLC: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with NSCLC received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG007","title":"Combination A Phase 2 First Line (1L) NSCLC: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with NSCLC received utomilumab 100 mg IV Q4W for cycle 1 then utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W starting at cycle 2.","id":"OG008","title":"Combination A Phase 2 1L NSCLC: Utomilumab Then Utomilumab + Avelumab"},{"description":"During Phase 2 participants with NSCLC received avelumab 10 mg/kg administered IV Q2W for cycles 1 then utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W starting at cycle 2.","id":"OG009","title":"Combination A Phase 2 1L NSCLC: Avelumab Then Utomilumab + Avelumab"}],"paramType":"MEDIAN","populationDescription":"Full analysis set includes all randomized participants for Cohorts A1, A2, A3, A9, and A10 and all enrolled participants for Cohorts A4, A5, A6, A7, and A8 who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug to date of death from any cause or data censoring date, whichever occurred first (maximum up to 7.3 years)","title":"Overall Survival (OS) for Combination A","type":"SECONDARY","unitOfMeasure":"Months"}